keyword
MENU ▼
Read by QxMD icon Read
search

Fidaxomicin

keyword
https://www.readbyqxmd.com/read/28332133/molecular-typing-and-antimicrobial-susceptibility-testing-to-six-antimicrobials-of-clostridium-difficile-isolates-from-three-czech-hospitals-in-eastern-bohemia-in-2011-2012
#1
V Beran, E J Kuijper, C Harmanus, I M Sanders, S M van Dorp, C W Knetsch, J Janeckova, A Seidelova, L Barekova, J Tvrdik, D Chmelar, I Ciznar
In 2011-2012, a survey was performed in three regional hospitals in the Czech Republic to determine the incidence of Clostridium difficile infections (CDIs) and to characterize bacterial isolates. C. difficile isolates were characterized by PCR ribotyping, toxin genes detection, multiple-locus variable-number tandem-repeat analysis (MLVA), and antimicrobial susceptibility testing to fidaxomicin, vancomycin, metronidazole, clindamycin, LFF571, and moxifloxacin using agar dilution method. The incidence of CDI in three studied hospitals was 145, 146, and 24 cases per 100,000 inhabitants in 2011 and 177, 258, and 67 cases per 100,000 inhabitants in 2012...
March 22, 2017: Folia Microbiologica
https://www.readbyqxmd.com/read/28331803/ivig-a-cure-to-severe-refractory-nap-1-clostridium-difficile-colitis-a-case-of-successful-treatment-of-severe-infection-which-failed-standard-therapy-including-fecal-microbiota-transplants-and-fidaxomicin
#2
Kelley Coffman, Xian Jie Cindy Chen, Charles Okamura, Eddie Louie
The mainstay treatment of Clostridium difficile infections (CDI) is antimicrobials with growing support for fecal microbiota transplants. We report the first case of an elderly man with severe refractory NAP-1 pseudomembranous CDI who failed all medical therapy and two fecal transplants with response only seen after administration of intravenous immunoglobulin.
2017: IDCases
https://www.readbyqxmd.com/read/28299963/cost-effectiveness-analysis-on-the-use-of-fidaxomicin-and-vancomycin-to-treat-clostridium-difficile-infection-in-france
#3
Maureen Watt, Aurélien Dinh, Alban Le Monnier, Patrick Tilleul
BACKGROUND: Fidaxomicin is a macrocyclic antibiotic with proven efficacy against Clostridium difficile infection (CDI) in adults. It was licensed in France in 2012, but, due to higher acquisition costs compared with existing treatments, healthcare providers require information on its cost/benefit profile. OBJECTIVE: To compare healthcare costs and health outcomes of fidaxomicin and vancomycin, as reference treatment for CDI. METHODS: A Markov model was used to simulate the treatment pathway, over 1 year, of adult patients with CDI receiving fidaxomicin or vancomycin...
March 16, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28286992/cadazolid-for-the-treatment-of-clostridium-difficile
#4
Bradley T Endres, Eugénie Bassères, M Jahangir Alam, Kevin W Garey
Antibiotic development goals for CDI include potent antimicrobial effect against C. difficile, limited killing of host microbiota, potential effect on spores, and ability to interfere with toxin production. Cadazolid, a novel, non-absorbable hybrid antibiotic has many of these criteria. In phase I and II clinical trials, cadazolid was shown to be safe, well tolerated, and efficacious positioning itself as a potential future viable therapeutic option for CDI. Areas covered: This review provides an in-depth evaluation of the chemistry, microbiology, pharmacodynamics, pharmacokinetics, and clinical trial results for cadazolid...
March 13, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28272217/recurrent-clostridium-difficile-infection-among-medicare-patients-in-nursing-homes-a-population-based-cohort-study
#5
Marya D Zilberberg, Andrew F Shorr, William M Jesdale, Jennifer Tjia, Kate Lapane
We explored the epidemiology and outcomes of Clostridium difficile infection (CDI) recurrence among Medicare patients in a nursing home (NH) whose CDI originated in acute care hospitals.We conducted a retrospective, population-based matched cohort combining Medicare claims with Minimum Data Set 3.0, including all hospitalized patients age ≥65 years transferred to an NH after hospitalization with CDI 1/2011-11/2012. Incident CDI was defined as ICD-9-CM code 008.45 with no others in prior 60 days. CDI recurrence was defined as (within 60 days of last day of CDI treatment): oral metronidazole, oral vancomycin, or fidaxomicin for ≥3 days in part D file; or an ICD-9-CM code for CDI (008...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28257555/antibiotic-treatment-for-clostridium-difficile-associated-diarrhoea-in-adults
#6
REVIEW
Richard L Nelson, Katie J Suda, Charlesnika T Evans
BACKGROUND: Clostridium difficile (C. difficile) is recognized as a frequent cause of antibiotic-associated diarrhoea and colitis. This review is an update of a previously published Cochrane review. OBJECTIVES: The aim of this review is to investigate the efficacy and safety of antibiotic therapy for C. difficile-associated diarrhoea (CDAD), or C. difficile infection (CDI), being synonymous terms. SEARCH METHODS: We searched MEDLINE, EMBASE, CENTRAL and the Cochrane IBD Group Specialized Trials Register from inception to 26 January 2017...
March 3, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28238947/identification-of-novel-mrp3-inhibitors-based-on-computational-models-and-validation-using-an-in-vitro-membrane-vesicle-assay
#7
Izna Ali, Matthew A Welch, Yang Lu, Peter W Swaan, Kim L R Brouwer
INTRODUCTION: Multidrug resistance-associated protein 3 (MRP3), an efflux transporter on the hepatic basolateral membrane, may function as a compensatory mechanism to prevent the accumulation of anionic substrates (e.g., bile acids) in hepatocytes. Inhibition of MRP3 may disrupt bile acid homeostasis and is one hypothesized risk factor for the development of drug-induced liver injury (DILI). Therefore, identifying potential MRP3 inhibitors could help mitigate the occurrence of DILI. METHODS: Bayesian models were developed using MRP3 transporter inhibition data for 86 structurally diverse drugs...
February 24, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28208717/final-demonstration-of-the-co-identity-of-lipiarmycin-a3-and-tiacumicin-b-fidaxomicin-through-single-crystal-x-ray-analysis
#8
Stefano Serra, Luciana Malpezzi, Angelo Bedeschi, Claudio Fuganti, Piera Fonte
Lipiarmycin A3 and tiacumicin B possess the same chemical structure and have been considered identical till recently, when some authors have suggested the possibility of a minor difference between the chemical structures of the two antibiotics. In this work we performed a comparative X-ray analysis of lipiarmycin A3 and tiacumicin B. Although the commercial samples of the aforementioned compounds crystallize into two different crystal systems-evidently due to the different crystallization conditions-their chemical structures are identical...
February 8, 2017: Antibiotics
https://www.readbyqxmd.com/read/28196423/fecal-microbiota-transplantation-is-there-a-role-in-the-eradication-of-carbapenem-resistant-klebsiella-pneumoniae-intestinal-carriage
#9
Ana Ponte, Rolando Pinho, Margarida Mota
The authors present the case of a 66-year-old woman with four hospitalizations due to recurrent Clostridium difficile infection (CDI) non responsive to vancomycin and fidaxomicin. Furthermore, intestinal colonization with carbapenem-resistant Klebsiella pneumoniae (CRKP) was identified after a positive stool culture in a screening routinely performed in our center in patients recently hospitalized.
February 15, 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28178052/fecal-microbiota-transplant-for-clostridium-difficile-infection-in-a-pregnant-patient
#10
Bejan J Saeedi, Doree Gardner Morison, Colleen S Kraft, Tanvi Dhere
BACKGROUND: Clostridium difficile infection has been associated with negative outcomes in the general population and in pregnant patients. Fecal microbiota transplant has become the standard for treatment of recurrent as well as refractory C difficile infection. CASE: We present a case of a 28-year-old pregnant woman who presented with recurrent C difficile infection despite treatment with vancomycin and fidaxomicin and underwent a successful fecal microbiota transplant through colonoscopy at 18 weeks of gestation...
March 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28172620/p390-open-label-study-to-evaluate-the-pharmacokinetics-of-fidaxomicin-in-inflammatory-bowel-disease-patients-with-clostridium-difficile-infection-the-profile-study-pharmacokinetics-analysis
#11
C Högenauer, Y Mahida, A Stallmach, P Marteau, G Rydzewska, V Ivashkin, P Gargalianos-Kakolyris, I Michon, N Adomakoh, W Reinisch
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28134686/novel-antibiotics-in-development-to-treat-clostridium-difficile-infection
#12
Eugénie Bassères, Bradley T Endres, Kierra M Dotson, M Jahangir Alam, Kevin W Garey
PURPOSE OF REVIEW: Clostridium difficile infections (CDI) remain a challenge to treat clinically due primarily to limited number of antibiotics available and unacceptably high recurrence rates. Because of this, there has been significant demand for creating innovative therapeutics, which has resulted in the development of several novel antibiotics. RECENT FINDINGS: This review updates seven different antibiotics that are currently in development to treat CDI including fidaxomicin, surotomycin, ridinilazole, ramoplanin, cadazolid, LFF571, and CRS3123...
January 2017: Current Opinion in Gastroenterology
https://www.readbyqxmd.com/read/28120176/fidaxomicin-for-treatment-of-clostridium-difficile-infection-in-clinical-practice-a-prospective-cohort-study-in-a-french-university-hospital
#13
Marie Pichenot, Rozenn Héquette-Ruz, Remi Le Guern, Bruno Grandbastien, Clément Charlet, Frédéric Wallet, Sophie Schiettecatte, Fanny Loeuillet, Benoit Guery, Tatiana Galperine
PURPOSE: Two randomized controlled trials (RCTs) showed the non-inferiority of fidaxomicin compared with vancomycin for Clostridium difficile infection (CDI) treatment and its superiority regarding recurrence rate. The aim of this study was to evaluate fidaxomicin's efficacy in clinical practice. METHODS: This single-center prospective cohort study included hospitalized patients treated with fidaxomicin for CDI. Demographic, clinical and biological data were collected...
January 24, 2017: Infection
https://www.readbyqxmd.com/read/28116471/-gastrointestinal-infections
#14
C Lübbert, R Mutters
Infectious diarrhea is one of the most common diseases. This article summarizes the current state of the diagnostics and treatment and includes the most important pathogens, i.e. Norovirus, Rotavirus, Campylobacter, Salmonella, Shigella and pathogenic Escherichia coli. Infections caused by toxin-producing strains of Clostridium difficile are described in more detail due to the increasing importance. Symptomatic therapy is still the most important component of treatment. Empirical antibiotic therapy is reserved for severely ill patients with a high stool frequency, fever, bloody diarrhea, underlying immune deficiency or significant comorbidities...
February 2017: Der Internist
https://www.readbyqxmd.com/read/28103289/cost-effectiveness-analysis-of-five-competing-strategies-for-the-management-of-multiple-recurrent-community-onset-clostridium-difficile-infection-in-france
#15
Emilie Baro, Tatiana Galperine, Fanette Denies, Damien Lannoy, Xavier Lenne, Pascal Odou, Benoit Guery, Benoit Dervaux
BACKGROUND: Clostridium difficile infection (CDI) is characterized by high rates of recurrence, resulting in substantial health care costs. The aim of this study was to analyze the cost-effectiveness of treatments for the management of second recurrence of community-onset CDI in France. METHODS: We developed a decision-analytic simulation model to compare 5 treatments for the management of second recurrence of community-onset CDI: pulsed-tapered vancomycin, fidaxomicin, fecal microbiota transplantation (FMT) via colonoscopy, FMT via duodenal infusion, and FMT via enema...
2017: PloS One
https://www.readbyqxmd.com/read/28096550/the-ups-and-downs-of-drug-discovery-the-early-history-of-fidaxomicin
#16
James B McAlpine
The path from antibiotic compound discovery to the market is marked by many potholes and its negotiation is often dependent on luck and persistence. Perhaps the prime example of this is the case of the development of tiacumicin B to Fidaxomicin, where both parameters were critical and the path was particularly circuitous.The Journal of Antibiotics advance online publication, 18 January 2017; doi:10.1038/ja.2016.157.
January 18, 2017: Journal of Antibiotics
https://www.readbyqxmd.com/read/28077203/clostridium-difficile-infection-in-older-adults-systematic-review-of-efforts-to-reduce-occurrence-and-improve-outcomes
#17
Leisa L Marshall, Samuel Peasah, Gregg A Stevens
OBJECTIVE: Provide a systematic review of the primary literature on efforts to reduce Clostridium difficile infection (CDI) occurrence and improve outcomes in older adults. DATA SOURCES, STUDY SELECTION, DATA EXTRACTION: PubMed and CINAHL databases were searched for research studies using search terms CDI, CDI prevention, reduction, control, management, geriatric, elderly, adults 65 years of age and older. The MeSH categories Aged and Aged, 80 and older, were used...
January 1, 2017: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/28027991/successful-treatment-of-severe-clostridium-difficile-infection-by-administration-of-crushed-fidaxomicin-via-a-nasogastric-tube-in-a-critically-ill-patient
#18
Sven Arends, Jerome Defosse, Cori Diaz, Frank Wappler, Samir G Sakka
OBJECTIVE: To report the successful use of crushed fidaxomicin via a nasogastric tube for treatment of a severe Clostridium difficile infection in a critically ill patient. DATA SOURCES: Clinical observation of a patient, images of abdominal computed tomography, antimicrobial therapy and course of infection parameters. DATA EXTRACTION: Relevant information contained in the medical observation of the patient and selection of image and laboratory parameters performed in the patient...
December 24, 2016: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28009682/outcomes-with-fidaxomicin-therapy-in-clostridium-difficile-infection
#19
Clayton M Spiceland, Sahil Khanna, Darrell S Pardi
BACKGROUND AND GOALS: Fidaxomicin is a new antibiotic used to treat Clostridium difficile infection (CDI). Given limited clinical experience with fidaxomicin, we assessed outcomes in a diverse cohort of patients with CDI treated with fidaxomicin. STUDY: All CDI cases treated with fidaxomicin at 3 referral centers over a 4-year period were included. Response was defined as resolution of diarrhea and recurrence was defined by recurrence of CDI within 8 weeks of the end of treatment...
December 22, 2016: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/27993853/in-vitro-activities-of-mcb3681-and-eight-comparators-against-clostridium-difficile-isolates-with-known-ribotypes-and-diverse-geographical-spread
#20
Jane Freeman, Sally Pilling, Jonathan Vernon, Mark H Wilcox
Treatments for Clostridium difficile infection remain limited, despite the introduction of fidaxomicin, and development of new agents is necessary. We determined the in vitro susceptibilities of 199 prevalent or emerging Clostridium difficile PCR ribotypes to MCB3681, a novel investigational quinolonyl-oxazolidinone, and 8 comparators (metronidazole, vancomycin, fidaxomicin, moxifloxacin, ciprofloxacin, clindamycin, tigecycline, and linezolid). MCB3681 showed good activity against C. difficile with no evidence of MCB3681 resistance in isolates showing either moxifloxacin or linezolid resistance or both moxifloxacin and linezolid resistance...
March 2017: Antimicrobial Agents and Chemotherapy
keyword
keyword
23034
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"